The approach of targeting TNFα has considerably improved success in the treatment of BS, in particular for patients with refractory, severe BS, and in particular for ocular, central nervous system, and gastrointestinal manifestations, as well as vascular involvement [6,9,15,16,17,18]. This evidence concerns the gene TNF and Bloom syndrome.